3D bioprinting has achieved a landmark breakthrough with researchers at the University of Wisconsin Madison recently developing a novel method for printing functional human brain tissue. Likewise, at the Vienna University of Technology, researchers have advanced in generating replacement tissue for potentially treating injured cartilage through lab-based 3D printing. These developments signify a crucial turning point in regenerative medicine, laying the foundation for the fabrication of intricate tissue structures, says data and analytics company GlobalData.
Ladanifer / shutterstock.com
1941498415
3d bioprinting
GlobalData’s technology innovation intelligence tool “Technology Foresights” indicates a consistent increase in the number of patents associated with 3D bioprinting over the years, totalling 2,868 between 2015 and 2023. The addition of 24 new companies to the patent landscape in 2023, bringing the total to 121, demonstrates a growing emphasis on innovating bioprinting technologies.
Kiran Raj, practice head of Disruptive Tech at GlobalData, said: “Bioprinting is revolutionising personalised medicine by going beyond the customisation of tools and prosthetics. It is about creating a new paradigm where medical interventions are not only tailored to the individual's unique biological makeup but also involve the bio fabrication of living tissues and organs. This technological leap has the potential to dramatically reduce transplant waitlists and enhance the compatibility of implants, minimising rejection rates. The precision in mimicking human tissues now enables treatments that were once considered futuristic, embodying a transformative step towards truly patient-centric healthcare solutions.”
Rahul Kumar Singh, senior analyst of Disruptive Tech at GlobalData, added: “The landscape of bioprinting extends beyond tissue engineering, venturing into the world of on-site medical implants and the pioneering efforts towards organ printing. The initiation of advanced trials, such as the assessment of 3D bio-printed regenerative breast implants using plant-derived collagen, showcases the innovative strides being made. Notably, the development of synthetic cartilage and functional human brain tissue through bioprinting signifies a monumental advancement in regenerative medicine. These developments, coupled with a surge in patent filings, reflect a vibrant, competitive atmosphere that's driving forward the boundaries of what's possible in medical technology and innovation.”
An analysis of GlobalData's Disruptor Intelligence Center highlights that strategic partnerships are driving innovation in the field of 3D bioprinting. The collaboration between NTU Singapore and industry leaders, aiming to advance 3D bioprinting for regenerative medicine, mirrors the commitment to push the boundaries of healthcare, akin to the advancements in printing functional brain tissue.
Similarly, the partnership between Stratasys and CollPlant Biotechnologies, focusing on the regenerative solutions like breast implants, showcases the potential of 3D bioprinting in creating complex tissues and organs, aligning with the innovative strides seen in brain tissue engineering.
Singh concludes: “While the advancements are remarkable, the journey ahead is filled with challenges in replicating biological complexity and ensuring biocompatibility. With the 3D bioprinting market expected to grow significantly, the potential impact on regenerative medicine is immense. Continuous research and technological refinement remain crucial.”
